N-(3-methoxybenzyl)thiophene-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: N-(3-methoxybenzyl)thiophene-2-carboxamide
• 英文别名: N-[(3-methoxyphenyl)methyl]thiophene-2-carboxamide
• 化学式: C₁₃H₁₃NO₂S
• mdl: MFCD04067420
• 分子量: 247.31
• InChiKey: NUIYOQQHFRWQOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Texas Heart Institute

  公开号：EP2640721A2

  公开（公告）日：2013-09-25
• COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES
  申请人：7 HILLS INTERESTS, LLC

  公开号：EP3164127A1

  公开（公告）日：2017-05-10
• [EN] AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS<br/>[FR] AGONISTES AMÉLIORANT LA LIAISON DE CELLULES EXPRIMANT DES INTÉGRINES À DES RÉCEPTEURS D'INTÉGRINES
  申请人：TEXAS HEART INST

  公开号：WO2012068251A2

  公开（公告）日：2012-05-24

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
• [EN] COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES<br/>[FR] COMPOSITIONS ET MÉTHODES D'AMÉLIORATION DE THÉRAPIES CELLULAIRES ADOPTIVES
  申请人：HILLS INTERESTS LLC 7

  公开号：WO2016003980A1

  公开（公告）日：2016-01-07

  Compositions and methods of enhancing the potency and efficacy of adoptive cell therapy using integrin-ligand stabilizers, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the effector cells ex vivo with agonists or stabilizers having the general Formula (I); methods of treating integrin-expressing cells with such stabilizers to enhance tumor infiltration; and therapeutic methods comprising administering stabilizer or agonist-treated cells to a mammal requiring treatment of solid tumors, hematologic cancers.